Danaher (NYSE:DHR) has agreed to acquire Masimo Corporation for $9.9 billion in a cash and stock deal, aiming to expand its presence in healthcare technology and diagnostic solutions. This acquisition positions Masimo as a standalone business within Danaher’s Diagnostics segment. The deal signifies Danaher’s strategic focus on diagnostics, coming at a time of mixed share performance for the company.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Danaher’s US$9.9b Masimo Deal Refocuses Growth On Diagnostics Valuation
Danaher (NYSE:DHR) has agreed to acquire Masimo Corporation for $9.9 billion in a cash and stock deal, aiming to expand its presence in healthcare technology and diagnostic solutions. This acquisition positions Masimo as a standalone business within Danaher’s Diagnostics segment. The deal signifies Danaher’s strategic focus on diagnostics, coming at a time of mixed share performance for the company.